Vaccines, Blood & Biologics
-
Labeling Request Memorandum, May 14, 2012 - MenHibrix
Date: May 14, 2012
To: 125363
From: David Staten, RPM
Subject: Labeling Request
Reference is made to the Hiberix (STN 125347) file to include a 0.9% sodium chloride diluent vial presentation manufactured by –b(4)-------------------. Changes had been made in the PI for this supplement that will pertain equally to the MenHibrix PI. In order to facilitate the review of the MenHibrix labeling, CBER requested a revised PI which contains the changes made to the Hiberix PI. GSK agreed.
-
-







